ProQR Therapeutics N.V. - SHS EURO (PRQR)

Historical Portfolio Holders from Q3 2014 to Q2 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / SHS EURO
Shares, excl. options Q2 2024
17.3M
Holdings value Q2 2024
$28.6M
Value change Q2 2024
-$213K
Grand Portfolio weight change Q2 2024
0%
Number of holders
47
Number of buys Q2 2024
7
Number of sells Q2 2024
-20
Average buys Q2 2024 %
+0%
Average sells Q2 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q2 17.3M $28.6M -$213K $1.66 47
2024 Q1 17.4M $39.8M -$2.34M $2.29 48
2023 Q4 18.4M $37M -$455K $1.98 46
2023 Q3 18.7M $24.3M -$3.6M $1.30 45
2023 Q2 21.1M $34.2M -$2.17M $1.62 51
2023 Q1 22.3M $47.5M +$11.1M $2.13 54
2022 Q4 16.7M $59.9M -$4.47M $3.70 45
2022 Q3 21.2M $15.9M -$761K $0.74 44
2022 Q2 22.1M $17.2M -$8.96M $0.78 47
2022 Q1 31.7M $28.7M -$92M $0.91 60
2021 Q4 45.4M $365M +$6.64M $8.01 72
2021 Q3 39.8M $333M +$12.2M $8.37 66
2021 Q2 38.5M $259M -$31.9M $6.74 61
2021 Q1 43.3M $286M +$116M $6.61 63
2020 Q4 26.4M $111M -$6.6M $4.20 47
2020 Q3 19.7M $94.3M -$5.25M $4.79 21
2020 Q2 29.1M $177M -$802K $6.08 44
2020 Q1 29.3M $161M -$7.18M $5.49 44
2019 Q4 30.2M $299M +$87.2M $9.91 51
2019 Q3 21.7M $125M -$19.1M $5.76 49
2019 Q2 23.6M $215M -$8.68M $9.10 55
2019 Q1 24M $333M +$6.36M $13.87 54
2018 Q4 23.1M $364M +$50.6M $15.78 57
2018 Q3 19.5M $378M +$169M $19.35 35
2018 Q2 11.1M $80.8M +$5.44M $7.30 24
2018 Q1 10.7M $32.9M -$2.76M $3.08 23
2017 Q4 11.5M $37.1M +$4.39M $3.22 26
2017 Q3 10.1M $48.9M +$5.21M $4.85 22
2017 Q2 9M $46.8M +$1.97M $5.20 18
2017 Q1 9.01M $45M +$634K $5.00 19
2016 Q4 8.89M $43.6M +$396K $4.90 22
2016 Q3 8.69M $58M -$2.94M $6.67 25
2016 Q2 9.15M $44.3M -$2.33M $4.84 26
2016 Q1 9.63M $46.9M -$10.8M $4.88 29
2015 Q4 11.2M $97.1M -$3.47M $8.68 32
2015 Q3 11.1M $162M +$3.97M $14.57 35
2015 Q2 10.8M $181M -$5.67M $16.67 36
2015 Q1 11M $241M +$65.7M $21.88 37
2014 Q4 8.02M $173M +$8.84M $21.67 35
2014 Q3 7.63M $130M +$130M $17.19 30